Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Acquired by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC grew its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 9.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 54,766 shares of the company’s stock after purchasing an additional 4,518 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in Dianthus Therapeutics were worth $1,194,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. R Squared Ltd acquired a new stake in shares of Dianthus Therapeutics in the 4th quarter valued at about $26,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Dianthus Therapeutics in the 4th quarter valued at about $33,000. KBC Group NV acquired a new stake in shares of Dianthus Therapeutics in the 4th quarter valued at about $35,000. BNP Paribas Financial Markets acquired a new stake in shares of Dianthus Therapeutics in the 4th quarter valued at about $59,000. Finally, AlphaQuest LLC raised its stake in shares of Dianthus Therapeutics by 273.1% in the 4th quarter. AlphaQuest LLC now owns 4,197 shares of the company’s stock valued at $91,000 after purchasing an additional 3,072 shares in the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

Wall Street Analysts Forecast Growth

DNTH has been the topic of several research reports. Robert W. Baird dropped their price objective on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an “outperform” rating on the stock in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Tuesday. Wedbush reiterated an “outperform” rating and set a $36.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Finally, Guggenheim reiterated a “buy” rating and set a $84.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $53.00.

Dianthus Therapeutics Trading Down 6.2%

Shares of NASDAQ:DNTH opened at $18.84 on Wednesday. The firm’s 50 day moving average is $19.68 and its two-hundred day moving average is $22.30. Dianthus Therapeutics, Inc. has a 52 week low of $13.37 and a 52 week high of $32.27. The firm has a market capitalization of $605.25 million, a P/E ratio of -7.54 and a beta of 1.48.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The company had revenue of $1.16 million for the quarter, compared to analyst estimates of $0.81 million. Analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.